The incidence of immune-mediated diseases is increasing worldwide. Reliable
immune markers for monitoring disease progression and also the effect of t
herapeutic interventions are urgently needed in order to investigate preven
tive or therapeutic measures effectively. At a recent workshop held on 5 De
cember 1998 in Copenhagen, the state of research on surrogate markers in Ty
pe 1 diabetes was discussed and compared with the experience in multiple sc
lerosis, inflammatory bowel disease and transplantation. Copyright (C) 1999
John Wiley & Sons, Ltd.